Diagnosis and treatment of pulmonary arterial hypertension: a review

NF Ruopp, BA Cockrill - Jama, 2022 - jamanetwork.com
Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension
(PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is …

[HTML][HTML] Risk stratification and medical therapy of pulmonary arterial hypertension

N Galiè, RN Channick, RP Frantz… - European …, 2019 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …

Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association

MA Konstam, MS Kiernan, D Bernstein, B Bozkurt… - Circulation, 2018 - Am Heart Assoc
Background and Purpose: The diverse causes of right-sided heart failure (RHF) include,
among others, primary cardiomyopathies with right ventricular (RV) involvement, RV …

Nitric oxide signalling in cardiovascular health and disease

C Farah, LYM Michel, JL Balligand - Nature Reviews Cardiology, 2018 - nature.com
Nitric oxide (NO) signalling has pleiotropic roles in biology and a crucial function in
cardiovascular homeostasis. Tremendous knowledge has been accumulated on the …

Pulmonary arterial hypertension: pathogenesis and clinical management

T Thenappan, ML Ormiston, JJ Ryan, SL Archer - Bmj, 2018 - bmj.com
Pulmonary hypertension is defined as a resting mean pulmonary artery pressure of 25 mm
Hg or above. This review deals with pulmonary arterial hypertension (PAH), a type of …

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis

MM Hoeper, K Dwivedi, C Pausch… - The Lancet …, 2022 - thelancet.com
Background Among patients meeting diagnostic criteria for idiopathic pulmonary arterial
hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion …

2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of …

N Galiè, M Humbert, JL Vachiery, S Gibbs… - European heart …, 2016 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …

[PDF][PDF] 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

N Galiè, M Humbert, JL Vachiery… - Polish Heart …, 2015 - journals.viamedica.pl
6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary …

M Humbert, G Kovacs, MM Hoeper… - European heart …, 2022 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Selexipag for the treatment of pulmonary arterial hypertension

O Sitbon, R Channick, KM Chin, A Frey… - … England Journal of …, 2015 - Mass Medical Soc
Background In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist,
was shown to be beneficial in the treatment of pulmonary arterial hypertension. Methods In …